HHS Secretary Robert F. Kennedy Jr. orders FDA review of abortion pill due to higher complication rates than reported, prompting calls for reinstating earlier safeguards. Study found severe complications in 10.93% of cases, much higher than FDA-reported rate of less than 0.5%.
Key Points
Study found 10.93% of women had severe complications after mifepristone abortions
Calls for reinstating safeguards around mifepristone due to safety concerns
FDA under scrutiny for lack of reporting and potential risks to women's health
Pros
Increased transparency on abortion pill safety
Potential for reinstating safeguards to protect women's health
Cons
Higher complication rates than previously reported
Potential risks to women's health due to lack of reporting and telehealth access